

# Peter C Taylor

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1324866/publications.pdf>

Version: 2024-02-01

142  
papers

8,311  
citations

61945

43  
h-index

51562

86  
g-index

156  
all docs

156  
docs citations

156  
times ranked

9926  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2017, 376, 652-662.   | 13.9 | 643       |
| 2  | Neutralizing monoclonal antibodies for treatment of COVID-19. <i>Nature Reviews Immunology</i> , 2021, 21, 382-393.  | 10.6 | 568       |
| 3  | Anti-TNF therapy: past, present and future. <i>International Immunology</i> , 2015, 27, 55-62.   | 1.8  | 455       |
| 4  | Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor $\hat{\pm}$ monoclonal antibody treatment in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1996, 39, 1077-1081.   | 6.7  | 408       |
| 5  | Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor $\hat{\pm}$ blockade in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2000, 43, 38-47.  | 6.7  | 378       |
| 6  | Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2009, 5, 578-582.   | 3.5  | 318       |
| 7  | Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes. <i>Cell Reports</i> , 2019, 28, 2455-2470.e5.   | 2.9  | 241       |
| 8  | Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 333-340.   | 0.5  | 232       |
| 9  | Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 761-772.   | 0.5  | 219       |
| 10 | A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. <i>Rheumatology International</i> , 2016, 36, 685-695.   | 1.5  | 201       |
| 11 | Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 196-202. | 0.5  | 194       |
| 12 | Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. <i>Arthritis Research and Therapy</i> , 2019, 21, 183.   | 1.6  | 181       |
| 13 | Pro-inflammatory activation of primary microglia and macrophages increases 18 kDa translocator protein expression in rodents but not humans. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 2679-2690.   | 2.4  | 153       |
| 14 | Development of a Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis. <i>PLoS ONE</i> , 2013, 8, e60635.  | 1.1  | 146       |
| 15 | Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 305-317.   | 6.3  | 145       |
| 16 | Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1042-1055.  | 2.9  | 135       |
| 17 | Incomplete response of inflammatory arthritis to TNF $\hat{\pm}$ blockade is associated with the Th17 pathway. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1741-1748.  | 0.5  | 133       |
| 18 | Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. <i>Current Opinion in Pharmacology</i> , 2010, 10, 308-315.  | 1.7  | 132       |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, i17-i26.  | 0.9  | 130       |
| 20 | Golimumab, a new human anti-tumor necrosis factor $\beta$ antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. <i>Arthritis and Rheumatism</i> , 2010, 62, 917-928.   | 6.7  | 116       |
| 21 | Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1475-1480.   | 0.5  | 107       |
| 22 | Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2119-2125.  | 0.5  | 105       |
| 23 | Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. <i>Nature Medicine</i> , 2022, 28, 1256-1268.  | 15.2 | 105       |
| 24 | A Systematic Review of Serum Biomarkers Anti-Cyclic Citrullinated Peptide and Rheumatoid Factor as Tests for Rheumatoid Arthritis. <i>Autoimmune Diseases</i> , 2011, 2011, 1-18.   | 2.7  | 102       |
| 25 | The Jak/STAT pathway: A focus on pain in rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 278-284.   | 1.6  | 97        |
| 26 | Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. <i>Lancet, The</i> , 2016, 388, 239-247.  | 6.3  | 95        |
| 27 | Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis. <i>Rheumatology International</i> , 2018, 38, 935-947.  | 1.5  | 89        |
| 28 | Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?. <i>Frontiers in Pharmacology</i> , 2019, 10, 279.   | 1.6  | 89        |
| 29 | Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC). <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1642-1652.   | 0.5  | 85        |
| 30 | Anti-TNF.ALPHA. Therapy for Rheumatoid Arthritis: An Update.. <i>Internal Medicine</i> , 2003, 42, 15-20.   | 0.3  | 83        |
| 31 | Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1853-1861.   | 0.5  | 83        |
| 32 | Antibody therapy for rheumatoid arthritis. <i>Current Opinion in Pharmacology</i> , 2003, 3, 323-328.   | 1.7  | 80        |
| 33 | Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol. <i>Trials</i> , 2019, 20, 429.   | 0.7  | 77        |
| 34 | Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 335-343.   | 0.5  | 71        |
| 35 | Efficacy and safety of rilonimab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial. <i>Arthritis Research and Therapy</i> , 2019, 21, 101. | 1.6  | 61        |
| 36 | The macrophage marker translocator protein (TSPO) is down-regulated on pro-inflammatory $\text{M1}^{\text{TM}}$ human macrophages. <i>PLoS ONE</i> , 2017, 12, e0185767.  | 1.1  | 59        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Patient Expectations and Perceptions of Goal-setting Strategies for Disease Management in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 2046-2054.  | 1.0 | 58        |
| 38 | Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 14-21.   | 1.0 | 57        |
| 39 | Tumour necrosis factor $\hat{\pm}$ as a therapeutic target for immune-mediated inflammatory diseases. <i>Current Opinion in Biotechnology</i> , 2004, 15, 557-563.   | 3.3 | 56        |
| 40 | How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?â€”MTX in the Treat-to-Target Strategy. <i>Journal of Clinical Medicine</i> , 2019, 8, 515.  | 1.0 | 54        |
| 41 | The value of sensitive imaging modalities in rheumatoid arthritis. <i>Arthritis Research</i> , 2003, 5, 210.   | 2.0 | 52        |
| 42 | The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis. <i>Frontiers in Immunology</i> , 2018, 9, 2226.   | 2.2 | 51        |
| 43 | Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial. <i>Journal of Clinical Medicine</i> , 2019, 8, 831.   | 1.0 | 50        |
| 44 | Association between maternal thyroid function and risk of gestational hypertension and pre-eclampsia: a systematic review and individual-participant data meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 243-252. | 5.5 | 49        |
| 45 | The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 509.  | 1.0 | 44        |
| 46 | The importance of the patients' experience of RA compared with clinical measures of disease activity. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, S28-31.  | 0.4 | 43        |
| 47 | Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 943-952.                           | 2.9 | 42        |
| 48 | Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 988-995.  | 0.5 | 41        |
| 49 | A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2021, 23, 85.                             | 1.6 | 41        |
| 50 | OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2123-2129.  | 0.5 | 39        |
| 51 | Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1033-1040.     | 0.5 | 39        |
| 52 | Anti- TNF $\hat{\pm}$ Therapy of Rheumatoid Arthritis: What Can We Learn about Chronic Disease?. <i>Novartis Foundation Symposium</i> , 2008, , 53-73.   | 1.2 | 38        |
| 53 | Filgotinib for the treatment of rheumatoid arthritis. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1181-1187.  | 1.9 | 36        |
| 54 | Role of biological agents in treatment of rheumatoid arthritis. <i>Pharmacological Research</i> , 2019, 150, 104497.   | 3.1 | 36        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Increase in circulating Th17 cells during anti-TNF therapy is associated with ultrasonographic improvement of synovitis in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 303.  | 1.6 | 35        |
| 56 | Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM. <i>Journal of Clinical Medicine</i> , 2019, 8, 1394.  | 1.0 | 35        |
| 57 | Systematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 1606-1616.   | 1.5 | 35        |
| 58 | Anti-inflammatory treatment improves high-density lipoprotein function in rheumatoid arthritis. <i>Heart</i> , 2017, 103, 766-773.   | 1.2 | 34        |
| 59 | B Cell Synovitis and Clinical Phenotypes in Rheumatoid Arthritis: Relationship to Disease Stages and Drug Exposure. <i>Arthritis and Rheumatology</i> , 2020, 72, 714-725.   | 2.9 | 33        |
| 60 | Quantitative Power Doppler Ultrasonography Is a Sensitive Measure of Metacarpophalangeal Joint Synovial Vascularity in Rheumatoid Arthritis and Declines Significantly Following a 2-week Course of Oral Low-dose Corticosteroids. <i>Journal of Rheumatology</i> , 2010, 37, 2493-2501.                         | 1.0 | 32        |
| 61 | Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation. <i>Trials</i> , 2019, 20, 182.  | 0.7 | 31        |
| 62 | The Clinical Features, Pathogenesis and Methotrexate Therapy of Chronic Chikungunya Arthritis. <i>Viruses</i> , 2019, 11, 289.   | 1.5 | 27        |
| 63 | Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials. <i>Rheumatology and Therapy</i> , 2020, 7, 173-190.   | 1.1 | 27        |
| 64 | Quantitative power Doppler ultrasound measures of peripheral joint synovitis in poor prognosis early rheumatoid arthritis predict radiographic progression. <i>Rheumatology</i> , 2016, 55, 89-93.   | 0.9 | 25        |
| 65 | Adopting PROs in virtual and outpatient management of RA. <i>Nature Reviews Rheumatology</i> , 2020, 16, 477-478.  | 3.5 | 24        |
| 66 | Treatment Satisfaction, Patient Preferences, and the Impact of Suboptimal Disease Control in a Large International Rheumatoid Arthritis Cohort: SENSE Study. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 359-373.   | 0.8 | 24        |
| 67 | Ultrasonographic measures of synovitis in an early phase clinical trial: a double-blind, randomised, placebo and comparator controlled phase IIa trial of GW274150 (a selective inducible nitric oxide) Tj ETQq1 1 0.78434 4 rgBTk Overlo  | 0.7 | 24        |
| 68 | Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 5-14.  | 1.3 | 22        |
| 69 | Plasma Levels of Eicosapentaenoic Acid Are Associated with Anti-TNF Responsiveness in Rheumatoid Arthritis and Inhibit the Etanercept-driven Rise in Th17 Cell Differentiation <i>In Vitro</i> . <i>Journal of Rheumatology</i> , 2017, 44, 748-756.   | 1.0 | 22        |
| 70 | Advances in positron emission tomography for the imaging of rheumatoid arthritis. <i>Rheumatology</i> , 2017, 56, 1837-1846.   | 0.9 | 22        |
| 71 | Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 658-666. | 0.5 | 22        |
| 72 | Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 890-898.  | 0.5 | 22        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Spondyloarthropathy: interleukin 23 and disease modification. <i>Lancet</i> , The, 2015, 385, 2017-2018.  | 6.3 | 21        |
| 74 | Editorial: Combination Cytokine Blockade: The Way Forward in Therapy for Rheumatoid Arthritis?. <i>Arthritis and Rheumatology</i> , 2015, 67, 14-16.  | 2.9 | 21        |
| 75 | Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment. <i>RMD Open</i> , 2018, 4, e000615.   | 1.8 | 20        |
| 76 | &lt;p&gt;Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making&lt;/p&gt;. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 119-131.  | 0.8 | 20        |
| 77 | Ultrasound of metacarpophalangeal joints is a sensitive and reliable endpoint for drug therapies in rheumatoid arthritis: results of a randomized, two-center placebo-controlled study. <i>Arthritis Research and Therapy</i> , 2012, 14, R198.   | 1.6 | 19        |
| 78 | TLR expression profiles are a function of disease status in rheumatoid arthritis and experimental arthritis. <i>Journal of Autoimmunity</i> , 2021, 118, 102597.  | 3.0 | 19        |
| 79 | Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials. <i>PLoS ONE</i> , 2016, 11, e0157961.  | 1.1 | 18        |
| 80 | TNF $\alpha$ regulates cortisol metabolism in vivo in patients with inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 464-469.  | 0.5 | 17        |
| 81 | The Development of Complex Digital Health Solutions: Formative Evaluation Combining Different Methodologies. <i>JMIR Research Protocols</i> , 2018, 7, e165.  | 0.5 | 16        |
| 82 | Anti-TNF $\alpha$ therapy for rheumatoid arthritis: an update. <i>Internal Medicine</i> , 2003, 42, 15-20.  | 0.3 | 15        |
| 83 | Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy. <i>RMD Open</i> , 2022, 8, e001994.  | 1.8 | 15        |
| 84 | Call for action: incorporating wellness practices into a holistic management plan for rheumatoid arthritisâ€”going beyond treat to target. <i>RMD Open</i> , 2021, 7, e001959.  | 1.8 | 14        |
| 85 | Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytrenâ€™s disease, with an embedded dose response study.. <i>Wellcome Open Research</i> , 2017, 2, 37. | 0.9 | 13        |
| 86 | Update on the diagnosis and management of early rheumatoid arthritis. <i>Clinical Medicine</i> , 2020, 20, 561-564.   | 0.8 | 13        |
| 87 | Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis. <i>Rheumatology</i> , 2022, 61, 3107-3122.  | 0.9 | 13        |
| 88 | Clinical application of a molecular assay for the detection of dermatophytosis and a novel non-invasive sampling technique. <i>Pathology</i> , 2016, 48, 720-726.   | 0.3 | 12        |
| 89 | Novel biomarkers of a peripheral blood interferon signature associated with drug-naïve early arthritis patients distinguish persistent from self-limiting disease course. <i>Scientific Reports</i> , 2020, 10, 8830.   | 1.6 | 12        |
| 90 | Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study. <i>Rheumatology</i> , 2021, 60, 2256-2266.  | 0.9 | 12        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Variation in the use of biologics in the management of rheumatoid arthritis across the UK. <i>Current Medical Research and Opinion</i> , 2012, 28, 1733-1741.   | 0.9 | 11        |
| 92  | Sustained multimodal antimicrobial stewardship in an Australian tertiary intensive care unit from 2008â€“2015: an interrupted time-series analysis. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 620-628.                                   | 1.1 | 10        |
| 93  | Maintenance of Efficacy and Safety with Subcutaneous Golimumab Among Patients with Active Rheumatoid Arthritis Who Previously Received Intravenous Golimumab. <i>Journal of Rheumatology</i> , 2011, 38, 2572-2580.   | 1.0 | 9         |
| 94  | Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trials. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 958-966. | 1.6 | 9         |
| 95  | A1.72â€“...Baricitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in an open-label, long-term extension study<sup>1</sup>. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A31.2-A31.                   | 0.5 | 8         |
| 96  | A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2021, 48, 1259-1267.   | 1.0 | 8         |
| 97  | MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 887-895.  | 1.0 | 7         |
| 98  | Patients with Rheumatoid Arthritis Acquire Sustainable Skills for Home Monitoring: A Prospective Dual-country Cohort Study (ELECTOR Clinical Trial I). <i>Journal of Rheumatology</i> , 2020, 47, 658-667.  | 1.0 | 7         |
| 99  | Targeted literature review of current treatments and unmet need in moderate rheumatoid arthritis in the United Kingdom. <i>Rheumatology</i> , 2021, 60, 4972-4981.  | 0.9 | 7         |
| 100 | Most Trial Eligibility Criteria and Patient Baseline Characteristics Do Not Modify Treatment Effect in Trials Using Targeted Therapies for Rheumatoid Arthritis: A Meta-Epidemiological Study. <i>PLoS ONE</i> , 2015, 10, e0136982.                            | 1.1 | 7         |
| 101 | Disease status in human and experimental arthritis, and response to TNF blockade, is associated with MHC class II invariant chain (CD74) isoform expression. <i>Journal of Autoimmunity</i> , 2022, 128, 102810.  | 3.0 | 7         |
| 102 | How do the efficacy and safety of abatacept and infliximab compare in the treatment of active RA?. <i>Nature Reviews Rheumatology</i> , 2009, 5, 126-127.   | 3.5 | 6         |
| 103 | Early Metacarpal Bone Mineral Density Loss Using Digital X-Ray Radiogrammetry and 3-Tesla Wrist MRI in Established Rheumatoid Arthritis: A Longitudinal One-Year Observational Study. <i>Arthritis</i> , 2015, 2015, 1-8.                                       | 2.0 | 6         |
| 104 | Protocol for evaluating and implementing a pragmatic value-based healthcare management model for patients with inflammatory arthritis: a Danish population-based regional cohort and qualitative implementation study. <i>BMJ Open</i> , 2018, 8, e023915.      | 0.8 | 6         |
| 105 | Influence of information provided prior to switching from Humira to biosimilar adalimumab on UK patientsâ€™ satisfaction: a cross-sectional survey by patient organisations. <i>BMJ Open</i> , 2022, 12, e050949.   | 0.8 | 6         |
| 106 | The JAK inhibitor baricitinib inhibits oncostatin M induction of proinflammatory mediators in ex-vivo synovial derived cells. <i>Clinical and Experimental Rheumatology</i> , 0, , .  | 0.4 | 6         |
| 107 | Factors influencing use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 2007-2014.  | 0.8 | 5         |
| 108 | The Parker Model: Applying a Qualitative Three-Step Approach to Optimally Utilize Input from Stakeholders When Introducing New Device Technologies in the Management of Chronic Rheumatic Diseases. <i>Patient</i> , 2018, 11, 515-526.                         | 1.1 | 5         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | Treating to target or treating the patient in rheumatoid arthritis?. <i>Lancet Rheumatology</i> , The, 2019, 1, e8-e10.  | 2.2 | 5         |
| 110 | Analysis of Immunogenicity Data in the Product Information of Biological Drugs: A Need to Report Immunogenicity Data Systematically. <i>BioDrugs</i> , 2019, 33, 683-691.  | 2.2 | 5         |
| 111 | Role of Hyaluronan in Human Adipogenesis: Evidence from in-Vitro and in-Vivo Studies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2675.   | 1.8 | 4         |
| 112 | When the first visit to the rheumatologist is established rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019, 33, 101479.   | 1.4 | 4         |
| 113 | Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib. <i>RMD Open</i> , 2021, 7, e001609.                           | 1.8 | 4         |
| 114 | OUP accepted manuscript. <i>Rheumatology</i> , 2019, 58, 2079-2080.  | 0.9 | 4         |
| 115 | Expression of Endogenous Putative TSH Binding Protein in Orbit. <i>Current Issues in Molecular Biology</i> , 2021, 43, 1794-1804.  | 1.0 | 4         |
| 116 | Itch as Major Mediator of Effect of Tofacitinib on Health-Related Quality of Life in Psoriatic Arthritis: A Mediation Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4081.                                  | 1.0 | 3         |
| 117 | Patient-reported outcome measures in systemic lupus erythematosus by a web-based application: A randomized, crossover, agreement study. <i>Lupus</i> , 2021, 30, 2124-2134.  | 0.8 | 3         |
| 118 | Decrease in articular hypoxia and synovial blood flow at early time points following infliximab and etanercept treatment in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 1072-1076. | 0.4 | 3         |
| 119 | A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 1-4.  | 1.3 | 2         |
| 120 | The Odd Couple?â€”Hardly. <i>Rheumatology</i> , 2017, 57, 1313-1315.   | 0.9 | 2         |
| 121 | Pain in Rheumatoid Arthritis: Could JAK Inhibition be the Answer?. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 112.   | 0.3 | 2         |
| 122 | Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of Baricitinib. <i>ACR Open Rheumatology</i> , 2022, 4, 254-258.  | 0.9 | 2         |
| 123 | Quality of Care in Rheumatoid Disease from the Clinician Perspective: A Modified Delphi Panel Approach. <i>Rheumatology and Therapy</i> , 2018, 5, 87-98.  | 1.1 | 1         |
| 124 | Relationship between thyroid hormones and metabolic syndrome in a normal thyroid function population in Western China. <i>Chinese Medical Journal</i> , 2021, Publish Ahead of Print, 350-352.                         | 0.9 | 1         |
| 125 | Evolving the comprehensive management of rheumatoid arthritis: identification of unmet needs and development of practical and educational tools. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1056-1067.  | 0.4 | 1         |
| 126 | Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies. <i>Journal of Dermatological Treatment</i> , 2022, , 1-28.             | 1.1 | 1         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 127 | P196 Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 9.3 years: an updated integrated safety analysis. <i>Rheumatology</i> , 2022, 61, .   | 0.9 | 1         |
| 128 | MRI-detected bone marrow edema in early rheumatoid arthritis. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 516-517.   | 3.2 | 0         |
| 129 | 223 [11C]PBR28 Macrophage Targeted Positron Emission Tomography Computed Tomography in Rheumatoid Arthritis: Results of a Pilot Study. <i>Rheumatology</i> , 0, , .  | 0.9 | 0         |
| 130 | Preface: Future trends in the field of spondyloarthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017, 31, 761-762.  | 1.4 | 0         |
| 131 | 244 The clinical phenotype of inflammatory arthritis correlates with synovial immune cell infiltration: results from the pathobiology of early arthritis cohort. <i>Rheumatology</i> , 2018, 57, .   | 0.9 | 0         |
| 132 | O09 A lymphoid pathotype at baseline, in early inflammatory arthritis, significantly associates with requirement for biologic therapy at 12 months follow up: results from the pathobiology of early arthritis cohort. <i>Rheumatology</i> , 2018, 57, . | 0.9 | 0         |
| 133 | O41 Predisposition of RA monocytes/macrophages to a pro-inflammatory phenotype through down-regulation of mitochondrial translocator protein. <i>Rheumatology</i> , 2018, 57, .  | 0.9 | 0         |
| 134 | Biosimilars: An Opportunity to Update the Product Information of Biological Drugs Regarding their Immunogenicity. <i>BioDrugs</i> , 2019, 33, 693-695.   | 2.2 | 0         |
| 135 | Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1439-1441.  | 0.5 | 0         |
| 136 | OP0350...ULTRASOUND POWER DOPPLER SEMI-QUANTITATIVE SCORING, IS IT TIME WE MOVED TO A RED PIXEL DENSITY ALGORITHMIC PROGRAM TO DETERMINE TRUE TREATMENT RESPONSE?. , 2019, , .   |     | 0         |
| 137 | OP0120...BASELINE CELLULAR AND MOLECULAR CHARACTERISTICS OF SYNOVIAL TISSUE AND RELATION WITH TNFI RESPONSE. RESULTS FROM THE PATHOBIOLOGY OF THE EARLY ARTHRITIS COHORT (PEAC). , 2019, , .   |     | 0         |
| 138 | Real-life drug persistence in patients with rheumatic diseases treated with CT-P13: a prospective observational cohort study (PERSIST). <i>Rheumatology Advances in Practice</i> , 2021, 5, rrab026.   | 0.3 | 0         |
| 139 | Central sensitisation: causes, therapies, and terminology. <i>Lancet Rheumatology</i> , The, 2021, 3, e546-e547.   | 2.2 | 0         |
| 140 | Risk of harm in synthetic and biological intervention trials in patients with inflammatory arthritis: protocol for a metaepidemiological study focusing on contextual factors. <i>BMJ Open</i> , 2021, 11, e049850.                                      | 0.8 | 0         |
| 141 | SB4 in the Era of Biosimilars: Clinical Data and Real-World Experience. <i>Mediterranean Journal of Rheumatology</i> , 2019, 30, 59.   | 0.3 | 0         |
| 142 | The JAK inhibitor baricitinib inhibits oncostatin M induction of proinflammatory mediators in ex-vivo synovial derived cells. <i>Clinical and Experimental Rheumatology</i> , 2021, , .  | 0.4 | 0         |